Multicenter phase II study of biweekly CAPIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer (JSWOG-C3 study)

BACKGROUND: Triweekly capecitabine plus irinotecan (CAPIRI) was not a replacement for fluorouracil, leucovorin, and irinotecan (FOLFIRI) in the treatment of metastatic colorectal cancer (mCRC) because of the potential for greater toxicity. Recently, it has reported that mCAPIRI is well tolerated and...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Int J Clin Oncol
Main Authors: Suzuki, Nobuaki, Hazama, Shoichi, Nagasaka, Takeshi, Tanioka, Hiroaki, Iwamoto, Yasuo, Negoro, Yuji, Yamauchi, Masami, Kobayashi, Michiya, Okuda, Hiroshi, Fujishima, Noriaki, Nishimura, Taku, Yamanaka, Naoki, Toyota, Kazuhiro, Mori, Yoshiko, Nakagami, Yuki, Shimokawa, Mototsugu, Nagano, Hiroaki, Okajima, Masazumi
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Singapore 2019
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6736909/
https://ncbi.nlm.nih.gov/pubmed/31144145
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10147-019-01473-3
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados